Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538910 · ClinicalTrials.gov registry record · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
A NA study of Major Depressive Disorder and Normal Physiology, sponsored by National Institute on Drug Abuse (NIDA).
- Recruiting
- Registry status
- NA
- Development phase
- 620
- Enrollment target
- 1
- Study location
NCT05538910 is a NA study of Major Depressive Disorder and Normal Physiology that is actively recruiting participants, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 620 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05538910, a NA study of Major Depressive Disorder and Normal Physiology, is actively recruiting participants, sponsored by National Institute on Drug Abuse (NIDA).
- RECRUITING
- Registry status
- NA
- Development phase
- 620 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brain function. Eligibility: People aged 18 to 60 years, at the time of consent, with and without MDD who do not smoke cigarettes or use other nicotine products. Design: Participants will have 2 or 3 study visits over 1 year. Participants will have 2 MRI scans no less than 4 days apart. Each scan visit will last 5 to 7 hours. At each scan, they will have urine and breath tests to screen for recent use of alcohol, nicotine, and illegal drugs. Before each scan, they will take 1 of 2 medications: nicotine or placebo. Participants will receive each medication once. They will not know which medication they are receiving at each scan. For each MRI scan, they will lie on a table that slides into a cylinder. Sometimes they will be asked to lie still. Sometimes they will complete tasks on a computer. Tasks may include identifying colors or playing games to win money. Each scan will take about 2 hours. Participants will answer questions about their thoughts, feelings, and behaviors before and after each scan. They will have a blood test after each scan.
Conditions Studied
Interventions
- DRUG Nicotine Patch
- OTHER Placebo Nicotine Patch
Study Locations (1)
Maryland
- National Institute on Drug Abuse - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05538910
The ClinicalTrials.gov registry entry for NCT05538910 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% higher). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT05538910 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05538910 about?
NCT05538910 is a clinical study titled "Defining Neurobiological Links Between Substance Use and Mental Illness". Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting comp...
What is the current status of trial NCT05538910?
This trial is currently recruiting. It is a NA study. The enrollment target is 620 participants. The study started on 2023-02-02. Estimated completion is 2027-12-31.
What conditions does trial NCT05538910 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Normal Physiology, Substance Use Disorder.
What interventions are being tested in trial NCT05538910?
The interventions under investigation include: Nicotine Patch (DRUG), Placebo Nicotine Patch (OTHER).
Who is sponsoring clinical trial NCT05538910?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05538910 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.